Search our science

Search our scientific publications and resources
on rare bleeding disorders

Study Phase
Content Type

Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.


Search Results

We found 359 resources matching your search criteria

Khan A, Wilkinson B, Shishko K, Hansen M, Doyle MJ, Triscott M, Ezban M. Measuring FIX-Activity of nonacog beta pegol (N9-GP) in a one-stage ellagic acid based clot assay on the ACL TOP 50 Series Instrument: A Two-site study. International Society on Thrombosis and Haemostasis - 64th Annual SSC Meeting. 2018;2(Suppl 1):74. PB158.
Chowdary P, Carcao M, Clausen WHO, Holme P, Moss J, Tosetto A, Wheeler A, Santagostino E. Correlation between the half-life of glycoPEGylated recombinant FVIII (N8-GP) and von Willebrand factor - results from phase 3 clinical trials. International Society on Thrombosis and Haemostasis - 64th Annual SSC Meeting. 2018;1(Suppl 1):84. PB175.
Primary manuscript
Rode F, Almholt K, Petersen M, Kreilgaard M, Kjalke M, Karpf D, Groth AV, Johansen P, Frost Larsen L, Loftager M, Haaning J. Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model. J Thromb Haemost. 2018;116(6):1141-1152.

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to